0001377121 false 0001377121 2021-08-04 2021-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2021

 

 

 

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37852   98-0505495
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

Protagonist Therapeutics, Inc.

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

 

(510) 474-0170

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.00001   PTGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

 

Item 1.01      Entry into a Material Definitive Agreement.

 

The Company and Zealand Pharma A/S (“Zealand”) entered into a collaboration agreement in June 2012 (the “Collaboration Agreement”). In October 2013, Zealand abandoned the collaboration, and the collaboration agreement was terminated in 2014. The abandonment of the collaboration was memorialized in an Abandonment Agreement dated as of February 28, 2014 (the “Abandonment Agreement”). The Collaboration Agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the Collaboration Agreement and which the Company elects to further develop following Zealand’s abandonment of the collaboration. Those obligations include development and sales milestone payments, as well as low-single digit royalties on net sales. The Company initially understood rusfertide to be a compound for which the post-termination payments described above are required under the Collaboration Agreement and therefore made three development milestone payments for an aggregate amount of $1.0 million under the Collaboration Agreement. However, upon re-evaluation, the Company concluded in 2019 that rusfertide is not a compound requiring post-termination payments under the agreement, and in 2020 initiated International Chamber of Commerce arbitration proceedings with Zealand related to the matter (the “Arbitration”).

 

The Company and Zealand resolved their dispute pursuant to an Arbitration Resolution Agreement, dated as of August 4, 2021 (the “Agreement”). Pursuant to the Agreement:

 

  a) the royalty rate payable by the Company on net sales of rusfertide has been reduced by 50%;

 

  b) all sales milestone payments on net sales of rusfertide have been reduced by 50%;

 

  c) all development milestones in respect of rusfertide have been reduced by 50%, except that the Company has agreed to pay in full within 2 business days after the effective date of the Agreement: (i) a $1.0 million development milestone for commencement of a Phase 2b rusfertide trial; and (ii) a $1.5 million development milestone that would otherwise have been due on initiation of a rusfertide Phase 3 trial (which trial the Company current expects to initiate in the first quarter of 2022).

 

  d) the Company is required to make an additional $1.5 million payment to Zealand in August 2022;

 

  e) each party will retain all payments previously made to it by the other party in connection with the Collaboration Agreement; and

 

  f) the parties have released claims related to the Collaboration Agreement, the Abandonment Agreement and the Arbitration.

 

Royalties, development milestone payments and sales milestone payments are due in respect of net sales and development made or achieved by either the Company or a Company licensee or collaborative partner. The Agreement relates only to rusfertide and not to any other compounds.

 

In addition to the payments specified in items (c) and (d) above, the Company expects, based on the anticipated number of patients in the rusfertide Phase 3 trial for polycythemia vera, that it may be required to pay Zealand up to $2.75 million in future rusfertide development milestone payments. Those payments include up to $1.0 million in the aggregate for registrational approvals (such as a New Drug Application approval by the United States Food and Drug Administration) and up to $1.75 million in the aggregate for commercial launch in the three geographic territories specified in the Collaboration Agreement (the United States, the European Union and the rest of the world, or “ROW”).

 

The reduced one-time sales milestone payments for rusfertide include up to an aggregate of $50 million based upon achievement of specified fiscal year net sales thresholds for the various territories.

 

The Company and Zealand have agreed to dismiss the Arbitration with prejudice, with each party bearing its own fees and costs.

 

The description of the terms and conditions of the Agreement set forth herein is not complete and is qualified in its entirety by reference to the text of the Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2021 and is incorporated herein by reference.

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Protagonist Therapeutics, Inc.
   
Dated: August 10, 2021  
  By:   /s/ Don Kalkofen
    Don Kalkofen
    Chief Financial Officer

 

3